APLM Profile
Apollomics, Inc. is a dynamic biotechnology company dedicated to the discovery and development of cutting-edge oncology therapies aimed at addressing significant unmet medical needs. The company's operations span across key global locations, including California, Hangzhou, Shanghai, China, and Australia.
Apollomics is advancing a range of innovative drug candidates with a focus on treating various types of cancer. Notably, the company is developing APL-101 (Vebreltinib), a highly selective c-Met inhibitor designed to target non-small cell lung cancer and other advanced malignancies. APL-102 is another critical drug in its pipeline, featuring an oral active, small molecule formulation that acts as a multiple tyrosine kinase inhibitor with potential applications in liver, breast, and esophageal cancers. Additionally, APL-122 represents a promising tumor inhibitor candidate aimed at addressing cancers that affect the brain.
The company's research and development efforts are geared towards providing novel therapeutic solutions for challenging cancer types, leveraging advanced technology and scientific expertise to create impactful treatments. Apollomics' approach combines rigorous preclinical research with clinical trials to bring transformative therapies to market.
Originally known as CBT Pharmaceuticals, Inc., Apollomics rebranded to its current name in January 2019. Established in 2015 and headquartered in Foster City, California, Apollomics is positioned at the forefront of oncology research, with a global footprint that supports its mission to innovate and deliver life-changing therapies for cancer patients worldwide.
|
